Driving reinvestment in R&D for antibiotics and advocating their responsible use

WP3B: Stakeholder platform and external communication

Academic: Ursula Theuretzbacher, Center for Anti-Infective Agents, Austria
EFPIA: Nicole Mahoney, MSD

Partners: L.J.V. Piddock, N. Brown T. Guise, V. Wells (British Society of Antimicrobial Chemotherapy), C. Clift, D. Heymann, E. Ross (Chatham House, London)

The private partners in DRIVE-AB are: AstraZeneca AB, GlaxoSmithKline Research & Development, F. Hoffmann-La Roche Ltd, MSD, Astellas Pharma Europe LTD, Pfizer Limited and Sanofi-Aventis Research & Development


  1. Identify and engage stakeholders through the development of a broad multidisciplinary stakeholder platform
  2. Develop and implement a comprehensive communication/engagement strategy that will involve and engage all stakeholders
  3. Establish effective relationships via meetings with and between decision makers central to the implementation of a new business model by engaging them early and throughout the project
  4. Communicate effectively the project’s findings and advances to the public
  5. Establish effective communication internally to ensure the communication flow between all WPs and stakeholders via WP3B


For more detail about Work Package 3B progress, please see our past NEWSLETTERS.


Posters and handouts
DRIVE-AB SME Stakeholder Meeting Report
Article: Development of new antibiotics: taking off finally?
Article: Recent FDA Antibiotic Approvals: Good News and Bad News
Article: Antibiotic research and development: business as usual?


If you would like to become a stakeholder, please REGISTER YOUR INTEREST with us to let us know exactly how you or your organization would like to engage with the project.
Click here for a list of current Associate Partners